Egami Kimiyasu, Murohara Toyoaki, Shimada Toshifumi, Sasaki Ken-Ichiro, Shintani Satoshi, Sugaya Takeshi, Ishii Masahiro, Akagi Teiji, Ikeda Hisao, Matsuishi Toyojiro, Imaizumi Tsutomu
Department of Cardiology, Nagoya University Graduate School of Medicine, Kurume, Japan.
J Clin Invest. 2003 Jul;112(1):67-75. doi: 10.1172/JCI16645.
Although the renin angiotensin system (RAS) is a major regulator of vascular homeostasis, the role of the RAS in tumor angiogenesis is little understood. Here we show that host angiotensin II (ATII) type 1 (AT1) receptor plays an important role in angiogenesis and growth of tumor cells engrafted in mice. Subcutaneous B16-F1 melanoma-induced angiogenesis as assessed by tissue capillary density and microangiography was prominent in WT mice but was reduced in AT1a receptor-deficient (AT1a-/-) mice. Consequently, tumor growth rate was significantly slower, and the mouse survival rate was greater, in AT1a-/- mice than in WT mice. Tumor growth was also reduced in WT mice treated with TCV-116, a selective blocker of AT1 receptor. Because the beta-galactosidase gene was inserted into the AT1a gene locus in AT1a-/- mice, the site of beta-galactosidase expression represents the AT1a receptor expression in these mutant mice. In tumor-implanted AT1a-/- mice, the major site of the beta-galactosidase expression was macrophages in tissues surrounding tumors. Moreover, the number of infiltrated macrophages was significantly lower in AT1a-/- mice than in WT mice, and double-immunofluorescence staining revealed that these macrophages expressed VEGF protein intensively. Therefore, the host ATII-AT1 receptor pathway supports tumor-associated macrophage infiltration, which results in enhanced tissue VEGF protein levels. The host ATII-AT1 receptor pathway thereby plays important roles in tumor-related angiogenesis and growth in vivo.
尽管肾素血管紧张素系统(RAS)是血管稳态的主要调节因子,但RAS在肿瘤血管生成中的作用却鲜为人知。在此我们表明,宿主血管紧张素II(ATII)1型(AT1)受体在植入小鼠体内的肿瘤细胞的血管生成和生长中发挥重要作用。通过组织毛细血管密度和微血管造影评估,皮下接种B16-F1黑色素瘤诱导的血管生成在野生型(WT)小鼠中很显著,但在AT1a受体缺陷型(AT1a-/-)小鼠中则减少。因此,与WT小鼠相比,AT1a-/-小鼠的肿瘤生长速度明显较慢,小鼠存活率更高。用AT1受体的选择性阻滞剂TCV-116处理的WT小鼠的肿瘤生长也有所减少。由于β-半乳糖苷酶基因被插入到AT1a-/-小鼠的AT1a基因位点,β-半乳糖苷酶表达的部位代表了这些突变小鼠中AT1a受体的表达。在植入肿瘤的AT1a-/-小鼠中,β-半乳糖苷酶表达的主要部位是肿瘤周围组织中的巨噬细胞。此外,AT1a-/-小鼠中浸润的巨噬细胞数量明显低于WT小鼠,双重免疫荧光染色显示这些巨噬细胞强烈表达VEGF蛋白。因此,宿主ATII-AT1受体途径支持肿瘤相关巨噬细胞浸润,这导致组织VEGF蛋白水平升高。宿主ATII-AT1受体途径因此在体内肿瘤相关的血管生成和生长中发挥重要作用。